Impact News +++ Himax Technologies, Inc. Reports Third Quarter 2025 Financial Results; Provides Fourth Quarter Guidance (GlobeNewswire EN) +++ HIMAX Aktie -3,50%

HIKMA Aktie

>HIKMA Aktienkurs

18.2 EUR -10.8% (Tradegate)

Ask: 18.2 EUR / 600 Stück

Bid: 17.9 EUR / 600 Stück

Tagesumsatz: 657 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

HIKMA Aktie über LYNX handeln

Intraday

1 Jahr

>HIKMA Performance

1 Woche: -4,8%

1 Monat: -6,1%

3 Monate: -10,4%

6 Monate: -16,4%

1 Jahr: -10,4%

laufendes Jahr: -17,8%

>HIKMA Aktie

Name:

HIKMA PHARMACEUTIC.LS-,10

Land:

Großbritannien

Sektor:

Gesundheit

ISIN/ Wkn:

GB00B0LCW083 / A0HG69

Symbol/ Ticker:

H5P (Frankfurt)

Kürzel:

FRA:H5P, ETR:H5P, H5P:GR

Index:

FTSE100

Webseite:

http://www.hikma.com/

Profil:

Hikma Pharmaceuticals PLC is a publicly traded mul..
>Volltext..

Marktkapitalisierung:

4423.68 Mio. EUR

Unternehmenswert:

5556.53 Mio. EUR

Umsatz:

2962.96 Mio. EUR

EBITDA:

647.68 Mio. EUR

Nettogewinn:

341.61 Mio. EUR

Gewinn je Aktie:

1.54 EUR

Schulden:

1355.27 Mio. EUR

Liquide Mittel:

205.29 Mio. EUR

Operativer Cashflow:

412.84 Mio. EUR

Bargeldquote:

0.11

Umsatzwachstum:

2.42%

Gewinnwachstum:

25.32%

Dividende je Aktie:

0.72 EUR

Dividendenrendite:

3.61%

Dividendenschätzung:

3.64%

Div. Historie:

14.08.25 - 0.30888€
20.03.25 - 0.41184€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

HIKMA

Letzte Datenerhebung:

06.11.25

>HIKMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 220.43 Mio. St.

Frei handelbar: 67.62%

Leerverk. Aktien: 0.5%

Rückkaufquote: 0.83%

Mitarbeiter: 9500

Umsatz/Mitarb.: 0.28 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 56.58%

Bewertung:

KGV: 12.33

KGV lG: 9.41

KUV: 1.64

KBV: 1.9

PEG-Ratio: 0.52

EV/EBITDA: 8.58

Rentabilität:

Bruttomarge: 40.33%

Gewinnmarge: 11.53%

Operative Marge: 15.39%

Managementeffizenz:

Gesamtkaprendite: 7.27%

Eigenkaprendite: 15.66%

>HIKMA Peer Group

Es sind 82 Aktien bekannt.

>HIKMA Chart & Kurs - Tradegate

>HIKMA News

06.11.25 - 09:36	Hikma Pharma tumbles as injectables guidance cut (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 09:06	Hikma lowers medium-term outlook despite reiterating 2025 guidance (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.10.25 - 07:00	These are the FTSE 100 stocks I expect to rally: Melrose, Hikma, and… (Fool)
	The FTSE 100 may be near an all-time high, but that doesn't mean all stocks are more expensive than they have been. Dr James Fox shares some value ideas. The post These are the FTSE 100 stocks I expect to rally: Melrose, Hikma, and… appeared first on The Motley Fool UK....

18.09.25 - 14:24	Director dealings: Hikma vice chair invests, Kier executives offload shares (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

22.08.25 - 20:36	Director dealings: Hikma Pharmaceuticals director raises stake (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

22.08.25 - 14:18	IN BRIEF: Hikma Pharmaceuticals director buys PS64,000 in shares (Alliance)
	Hikma Pharmaceuticals PLC - London-based drugmaker with operations in Jordan and US - Non-Executive Director Laura Balan buys...

11.08.25 - 15:18	DIRECTOR DEALINGS: Hikma Pharma vice chair buys after share price fall (Alliance)
	The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and Monday...

07.08.25 - 12:27	Hikma shares drop 7% on weaker margins despite solid revenue, maintained outlook (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 11:24	FTSE 100 Live: Stocks drop due to ex-div flurry, WPP and Hikma drop (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 11:06	Hikma Pharmaceuticals keeps guidance despite lower core profit at interim (Alliance)
	Hikma Pharmaceuticals PLC on Thursday said it continues to expect revenue and profit growth in 2025, despite core operating...

07.08.25 - 08:48	Hikma Posts Solid H1 Results, Reaffirms Strong Growth Outlook For 2025 (AFX)
	LONDON (dpa-AFX) - Hikma Pharmaceuticals plc (HIK.L), on Thursday, reported solid performance for the first half of 2025, reaffirming its guidance for strong growth in the second half of the year.......

14.07.25 - 11:30	Hikma Pharma Announces Launch Of Morphine Sulfate Injection In The US (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Hikma Pharmaceuticals has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe ......

04.07.25 - 13:24	FDA approves Hikma’s Tyzavan for multiple infections (PBR)
	Tyzavan is indicated for the treatment of several serious infections in adults and children one month and above, including septicemia, infective endocarditis, skin and skin structure infections, bone The post FDA approves Hikma's Tyzavan for multiple infections appeared first on Pharmaceutical Business review....

02.07.25 - 14:48	Hikma Gets FDA Approval For TYZAVAN Vancomycin Injection (AFX)
	LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK) Wednesday said that the US Food and Drug Administration (FDA) has approved TYZAVAN, a ready-to-infuse formulation of vancomycin.TYZAVAN is indica......

02.07.25 - 14:03	Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US (PR Newswire)
	Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse......

30.06.25 - 11:01	UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers (DailyMail)
	Britain's pharmaceutical sector still faces potential for further tariffs, as well as suggestions the White House could clamp down on the price of medicines in the US....

30.06.25 - 08:42	Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.06.25 - 17:01	Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines (PR Newswire)
	Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest......

10.06.25 - 13:06	DIRECTOR DEALINGS: Hikma exec and AB Dynamics advisor sell shares (Alliance)
	The following is a round-up of share dealings by London-listed company directors and managers announced so far this week and not separately reported by Alliance......

27.05.25 - 08:48	Bio-Thera Solutions And Hikma Pharma Say FDA Approved STARJEMZA Injection (AFX)
	LONDON (dpa-AFX) - Bio-Thera Solutions Ltd and Hikma Pharmaceuticals PLC announced that the U.S. Food and Drug Administration has approved STARJEMZA (ustekinumab-hmny) Injection, a biosimilar refe......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Dahingegangenen bleiben mit dem Wesentlichen, womit sie auf uns gewirkt haben, mit uns lebendig, solange wir leben. - Hermann Hesse

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram